Clinical Trial Update: Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 trial of ACC-001 in mild-to-moderate Alzheimer's disease completed, and results assessing safety, tolerability, and immunogenicity were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-01-01